"End of the year is a best guess for a vaccine" - Philip Noone on the global race for COVID vaccine
Update: 2020-08-25
Description
Aalto Bio is amongst a number of companies working on a vaccine for COVID-19.
The Dublin-based biotech company researches and develops proteins and reagents that are provided to pharmaceutical companies that in turn develop diagnostic tests for viruses.
CEO of Aalto Bio, Philip Noone who has been working in the virus diagnostics space for twenty-five years, says his company has been working on the clinical trials with a couple of companies who are developing vaccines. They include the American pharma giant, Moderna.
Noone told Sonya Lennon, host of The Architects of Business, made in partnership with EY Entrepreneur Of The Year™, about the pace at which the vaccine development is happening:
"Moderna have done their phase two clinical trials. You do three phases of clinical trials before you bring the product to market.
"They're in their third phase and they're probably moving at a speed faster than anybody else.
"So, we've been working hand in hand with them, helping them with their clinical trials in order to get a vaccine on the market faster. "
He goes onto explain on the podcast why he thinks a vaccine will be available before the end of the year.
The Dublin-based biotech company researches and develops proteins and reagents that are provided to pharmaceutical companies that in turn develop diagnostic tests for viruses.
CEO of Aalto Bio, Philip Noone who has been working in the virus diagnostics space for twenty-five years, says his company has been working on the clinical trials with a couple of companies who are developing vaccines. They include the American pharma giant, Moderna.
Noone told Sonya Lennon, host of The Architects of Business, made in partnership with EY Entrepreneur Of The Year™, about the pace at which the vaccine development is happening:
"Moderna have done their phase two clinical trials. You do three phases of clinical trials before you bring the product to market.
"They're in their third phase and they're probably moving at a speed faster than anybody else.
"So, we've been working hand in hand with them, helping them with their clinical trials in order to get a vaccine on the market faster. "
He goes onto explain on the podcast why he thinks a vaccine will be available before the end of the year.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
